Migralia
Migralia provides an online, drug-free reprocessing therapy designed to address the root neurobiological causes of chronic migraine rather than just suppressing symptoms. The program, delivered via video call, targets subconscious emotional patterns and nervous system regulation, with the company reporting a 97% improvement rate within the first four weeks. It includes a free 45-minute clinical assessment to determine patient suitability before enrollment.
- Healthcare Technology
- Digital Health
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Migraine sufferers often cycle through medications, physiotherapy, psychotherapy, and dietary changes without achieving lasting relief. Many live in constant anticipation of the next debilitating episode, organizing their lives around avoiding triggers, which compounds the frustration and biological hypervigilance that keep the condition active.
Solution
Migralia offers an online, drug-free reprocessing therapy that intervenes on the neurobiological origin of migraine rather than suppressing symptoms. The method targets the subconscious emotional automatisms that keep the nervous system on alert, using neuroscience-based techniques to regulate the nervous system and release stored emotional memories. By leveraging neuroplasticity and epigenetic principles, the therapy helps patients "unlearn" pain responses and restore internal security. Clinical data from the company reports a 97% improvement rate within the first four weeks, and the commitment includes a minimum 80% reversal of symptoms.
Target Audience
Primary customers are adults who have suffered from recurrent, incapacitating migraines for years, who have tried traditional treatments without durable results, and who are seeking a definitive, drug-free alternative.
Features
- Online delivery via video call, enabling remote participation from any location
- Clinical-emotional approach based on neuroscience, pain reprocessing therapy, bioneuroemotion, epigenetics, and subconscious reprogramming
- Targets the subconscious, where 95% of biological response is said to reside, intervening on non-conscious emotional automatisms
- Regulates the nervous system to deactivate pain circuits and reduce hypervigilance
- Free 45-minute clinical assessment interview to evaluate patient suitability before the program begins
- Reported 97% improvement rate within the first four weeks and a therapeutic guarantee of 80% minimum reversal